Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Enzymes, such as γ-secretase, are able to cleave and release the extracellular domain of BCMA into the bloodstream as soluble ...

VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

Subtle differences in an mRNA sequence enables a ribosome to produce more or less of a certain protein. A new AI model called ...

In The Lancet Diabetes & Endocrinology, Jean Claude Katte and colleagues report the results of the cross-sectional ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

This influx of resources and expertise is expected to drive the maturity of AI applications in antibody drug design, enhancing the potential for novel therapeutic candidates.

Latent Labs is backed by Radical Ventures, Sofinnova Partners, Google’s Chief Scientist Jeff Dean, Anthropic’s CEO Dario Amodei and Eleven Labs CEO Mati Staniszewski. About six months after coming out ...